Medicare Coverage of Innovative Technologies (MCIT)
The Centers for Medicare & Medicaid Services (CMS) is committed to ensuring people on Medicare have quicker access to innovative medical technologies for life-threatening or irreversibly debilitating diseases – like cancer and heart disease.In January 2021, we published a final rule called The Medicare Coverage of Innovative Technology and Definition of ‘Reasonable and Necessary’ (MCIT/R&N). The rule would have granted expedited Medicare coverage for up to four years for any U.S. Food & Drug Administration (FDA)-designated breakthrough device once the device received or cleared market authorization. For various reasons, CMS decided to repeal this rule and explore a new one. Public comment on the proposal will be open from September 15 until October 15. If the proposal is finalized, we intend to conduct future rule-making to explore an expedited coverage pathway that provides access to innovative beneficial technologies.